secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-06-02T20:00:20+00:00
Accession:  0001213900-26-064144
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio reports statistically significant white matter MRI biomarker in Phase 2 Alzheimer's trial
--------------------------------------------------------------------------------

- XPro1595 showed significant myelin improvement vs placebo in full mITT (p=0.0028, d=0.46, n=200).
- Biomarker-enriched patients (inflammation) showed stronger effect (p=0.0098, d=0.59, n=100).
- FDA granted Fast Track designation on May 14, 2026; End-of-Phase 2 alignment secured for Phase 2b/3.
- No ARIA-E or ARIA-H observed; favorable safety profile differentiates from amyloid-targeting therapies.
- Complete dataset to be presented at AAIC 2026 (July 12-15, London).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/0001213900-26-064144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/ea0293325-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-064144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer